Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

106
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
106
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

146
Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
146
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

147
Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
147
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

82
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
82
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

82
Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of...
82
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

133
Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...
133

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic Relevance of Erythropoiesis-Stimulating Agent Dose Requirements in PIVOTAL and its Implications for the Potential Mechanisms of Intravenous Iron Benefit in Maintenance Hemodialysis Patients.

American journal of nephrology·2026
Same author

Position statement of the SEN Anemia Working Group: A critical and contextualized adaptation of the KDIGO 2026 anemia guidelines to the Spanish setting.

Nefrologia·2026
Same author

Frailty and Congestion in Patients with Heart Failure: Clinical Interaction and Prognostic Implications.

Journal of clinical medicine·2026
Same author

Common Biomarkers of Endothelial Dysfunction Across Highly Prevalent Diseases with Cardiovascular Risk: Functional Characterization and Prognostic Implications.

International journal of molecular sciences·2026
Same author

Cardiovascular Trials in Hemodialysis: Closing the Evidence Gap.

Journal of the American College of Cardiology·2026
Same author

Effect of IV ferric carboxymaltose treatment on platelet counts and serum transferrin levels in CKD patients not on dialysis with iron deficiency: potential implications for thrombogenicity.

Renal failure·2026

Related Experiment Video

Updated: Oct 12, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K

Iron Deficiency in CKD Without Concomitant Anemia.

Jay B Wish1, Stefan D Anker2,3,4, Javed Butler5

  • 1Division of Nephrology, Indiana University Health, Indianapolis, Indiana, USA.

Kidney International Reports
|November 22, 2021
PubMed
Summary

Iron deficiency (ID) in chronic kidney disease (CKD) is distinct from anemia and warrants treatment regardless of hemoglobin levels. Addressing ID alone may improve outcomes in CKD patients, similar to heart failure patients.

Keywords:
anemiachronic kidney diseaseheart failureiron deficiency

More Related Videos

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

938
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.1K

Related Experiment Videos

Last Updated: Oct 12, 2025

Assessment of Vascular Function in Patients With Chronic Kidney Disease
08:50

Assessment of Vascular Function in Patients With Chronic Kidney Disease

Published on: June 16, 2014

16.4K
5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats
05:34

5/6 Nephrectomy Using Sharp Bipolectomy Via Midline Laparotomy in Rats

Published on: April 4, 2025

938
A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

21.1K

Area of Science:

  • Nephrology
  • Cardiology
  • Hematology

Background:

  • Iron's physiological role extends beyond red blood cell production.
  • Iron deficiency (ID) and anemia in chronic kidney disease (CKD) are distinct but interrelated.
  • Current CKD management prioritizes anemia correction over iron repletion.

Purpose of the Study:

  • Differentiate iron deficiency from anemia in CKD.
  • Review evidence linking iron repletion to outcomes in heart failure (HF) and CKD.
  • Explore potential benefits of iron therapy in CKD irrespective of anemia.

Main Methods:

  • Epidemiological and pathophysiological analysis of ID and anemia in CKD.
  • Review of clinical studies on iron therapy in heart failure with reduced ejection fraction (HFrEF).
  • Examination of evidence for iron therapy in CKD patients with or without anemia.

Main Results:

  • Iron deficiency is a distinct clinical entity from anemia in CKD.
  • Iron repletion improves outcomes in HFrEF patients.
  • Evidence suggests potential benefits of iron therapy in CKD independent of anemia.

Conclusions:

  • Iron deficiency management in CKD requires re-evaluation beyond anemia correction.
  • Further research is needed to establish optimal iron therapy strategies in CKD.
  • Clinicians should consider iron status in CKD management, especially in patients with HF comorbidities.